Research

Energy balance

The review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals.

The review may provide insights into the safety profile of these medications for practitioners.

StrongSupportsmedium confidence
This review intends to indirectly compare the adverse events of available glucagon-like peptide-1 receptor agonist pharmaceuticals.
Christoffer Storm Baden et al. · Adverse Drug Reaction Bulletin · 2023

Why this rating

The review aims to synthesize findings from existing studies.

Source

Safety of glucagon-like peptide-1 receptor agonists for weight management in adults, adolescents, and children with obesity: a scoping review

Christoffer Storm Baden et al. · Adverse Drug Reaction Bulletin · 2023

DOI 10.1097/fad.0000000000000067

reviewCited 2×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →